17 Left in Darkness: Blinded by Politics and Those in Power
Investigation by Ruwan Weerakoon
(Lanka-e-News -18 Nov 2026, 4.30 P.M.)Seventeen patients went for treatment and lost their eyesight. Compensation is being paid from public funds, so ordinary citizens who were not involved are also footing the bill. Meanwhile, the question of who is responsible for the failure has no clear answer, and public faith in justice is wearing thin.
A second health scandal raises the same question. Registrar of Companies records and National Medicines Regulatory Authority (NMRA) reports show that only one man has been charged over locally bottled, substandard intravenous immunoglobulin (IVIG) and human albumin vials. In contrast, others tied to the same company quietly walked away.
The Isolez Immunoglobulin Cover-Up Exposed
Company registry filings show two co-shareholders of Isolez Biotech Pharma handed over all their shares. Registrar of Companies records and NMRA reports raise a troubling question. Why has only one man been charged over locally bottled, substandard IVIG and human albumin vials, while others tied to the same company quietly left?
Documents examined in this investigation point to repeated regulatory warnings, a high-level state meeting attended by a Presidential Secretariat official, and a sudden transfer of shares just as the scandal reached the police. Together they suggest the criminal investigation may have stopped well short of those who built and benefited from the venture.
Born in 2016, Warned in 2022: A Factory the Regulator Never Approved
Company records show Isolez Biotech Pharma AG Limited was incorporated on August 24, 2016, during the Yahapalana administration. It was presented as a local manufacturer of pharmaceuticals, operating from a facility at Katunayake-Amandoluwa.
The regulator saw the facility differently. The NMRA repeatedly flagged the site as unsuited to sterile pharmaceutical production, the standard that life-saving injectable products such as IVIG and albumin must meet.
“Not Fit for Sterile Production”: NMRA’s Verdict Ignored
A February 2022 NMRA inspection report (NMRA/MFRD/LM-01-22) formally stated that the facility failed Good Manufacturing Practice (GMP) standards. More than a year later, in April 2023, NMRA Chief Executive Officer Dr. Vijith Gunasekera issued a final ruling. It reaffirmed that the site could not be approved for sterile drug production. The reports also flagged a hazardous practice: standard pharmaceuticals and cytotoxic (anti-cancer) drugs were being produced on the very same manufacturing line, which creates a serious risk of cross-contamination.
The regulator’s position was therefore clear and consistent, in writing, across more than a year. The question is what happened next.
The Presidential Secretariat at the Table
Despite these rejections, the documents suggest that state attention was directed at the project. On January 26, 2023, a special technical meeting was chaired by the Secretary of the Ministry of Health, with NMRA officials in attendance. The participation log lists Mr. Srinath Gamage, Director at the Presidential Secretariat, as the ninth attendee.
Attendance at a meeting is not proof of wrongdoing, and this report makes no such allegation. But it does raise legitimate questions. Why was an official from the Presidential Secretariat present at a technical meeting on a facility the regulator had already found wanting? Analysts and investigative observers have also linked the meeting to wider interventions by former presidential staffers and to progress review meetings held under the Ministry of Finance, which then fell under the presidency. They question whether executive pressure was applied to fast-track a local manufacturer that could not meet safety standards.
Mr. Gamage and the relevant offices have the right to explain their role, and the public deserves that explanation. October 10, 2023: The Day Two Shareholders Vanished
The most striking discrepancy lies in the company’s share records.
The company’s initial 100 shares were divided among three people:
• Tuduwage Malith Perera: 10 shares
• Tuduwage Manoj Perera: 30 shares
• Hewage Sudath Janaka Fernando: 60 shares
Days later, on October 10, 2023, both Malith Perera and Manoj Perera transferred all 40 of their shares to Sudath Janaka Fernando. This is recorded in Section 12 of the Registrar of Companies returns, which lists persons who have ceased to hold shares.
In a single transaction, two of the three original shareholders exited the company completely. The third was left holding all 100 shares and, as the records stand, all the legal exposure.
One Suspect, Many Questions: The Investigators’ Blind Spot
Mr. Sudath Janaka Fernando is currently on remand as the first suspect. He is the only person to have been arrested and charged. The questions below follow from the records, and they are questions, not accusations:
• Why did two co-shareholders give up their entire stakes immediately after the CID complaint was filed?
• Were they the real financial beneficiaries of the scheme?
• Did they act on inside information, and if so, did it come from ministry or presidential circles?
• Did investigators examine the timing of the transfers, or the departure of the partners, at all?
On the evidence in the Registrar’s records, the investigation appears to have focused on one man while the sudden exit of his partners went unexamined. If investigators did look into it, the public has not been told.
Who Overrode the Safety Warnings?
Independent company documents suggest a familiar pattern. Low-level or proxy operatives face the courts, while those who may have helped establish and operate a non-compliant pharmaceutical bottling plant remain shielded.
A truly comprehensive investigation would need to answer several things:
• Why the shareholders dissolved their stakes at the exact moment of exposure.
• Who financed and profited from the operation.
• Which administrative and political actors engaged with the project after the NMRA had rejected it, and whether any of them overrode or pressured the regulator.
Patients who received these products, many of them seriously ill, are the real victims of this scandal. They are owed more than a single prosecution.
If the regulator said no, and the shareholders left the moment the CID moved, who gave the order to go ahead, and why are they still untouched?
ATTENTION: PUBLIC CORRUPTION HURTS EVERY CITIZEN. SPEAK UP.
Do you know of corruption by any individual or group?
Evidence or no evidence, tell us.
Prefer to talk? Send your telephone number to our email, and one of our investigators will call you on a safe, secure telephone line.
✔️ 100% Confidential
✔️ Your identity is protected
✔️ No evidence needed to start
Report corruption. Serve the nation.
Lanka e-News Investigations Desk
by Ruwan Weerakoon
---------------------------
by (2026-11-18 12:29:25)
We are unable to continue LeN without your kind donation.
Read 2070 Times
Leave a Reply